PL4092025T3 - Kompozycja farmaceutyczna tricyklicznego związku będącego podwójnym inhibitorem pde3/pde4 - Google Patents
Kompozycja farmaceutyczna tricyklicznego związku będącego podwójnym inhibitorem pde3/pde4Info
- Publication number
- PL4092025T3 PL4092025T3 PL21741236.0T PL21741236T PL4092025T3 PL 4092025 T3 PL4092025 T3 PL 4092025T3 PL 21741236 T PL21741236 T PL 21741236T PL 4092025 T3 PL4092025 T3 PL 4092025T3
- Authority
- PL
- Poland
- Prior art keywords
- pde3
- tricyclic
- pharmaceutical composition
- inhibitor compound
- dual inhibitor
- Prior art date
Links
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 title 1
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 229940125436 dual inhibitor Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010042865 | 2020-01-15 | ||
| PCT/CN2021/072145 WO2021143841A1 (zh) | 2020-01-15 | 2021-01-15 | 三并环类pde3/pde4双重抑制剂化合物的药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4092025T3 true PL4092025T3 (pl) | 2024-10-28 |
Family
ID=76863620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21741236.0T PL4092025T3 (pl) | 2020-01-15 | 2021-01-15 | Kompozycja farmaceutyczna tricyklicznego związku będącego podwójnym inhibitorem pde3/pde4 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230060174A1 (pl) |
| EP (1) | EP4092025B9 (pl) |
| JP (2) | JP7712276B2 (pl) |
| KR (1) | KR20220127845A (pl) |
| CN (3) | CN119909076A (pl) |
| CA (1) | CA3167378A1 (pl) |
| ES (1) | ES2995084T3 (pl) |
| PL (1) | PL4092025T3 (pl) |
| WO (1) | WO2021143841A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4092025T3 (pl) * | 2020-01-15 | 2024-10-28 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Kompozycja farmaceutyczna tricyklicznego związku będącego podwójnym inhibitorem pde3/pde4 |
| CN114929701B (zh) * | 2020-01-15 | 2024-11-05 | 正大天晴药业集团股份有限公司 | 一种pde3/pde4双重抑制剂的结晶及其应用 |
| US20250171436A1 (en) * | 2022-01-21 | 2025-05-29 | Xizang Haisco Pharmaceutical Co., Ltd. | Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use Thereof |
| CN118105342A (zh) * | 2023-09-28 | 2024-05-31 | 立生医药(苏州)有限公司 | 一种含pde-4抑制剂的无菌吸入用混悬液及其制备方法和应用 |
| CN120136868A (zh) * | 2023-12-13 | 2025-06-13 | 石家庄以岭药业股份有限公司 | 三环稠杂环类pde3/4双重抑制剂及其制备方法与应用 |
| WO2026052051A1 (zh) * | 2024-09-06 | 2026-03-12 | 正大天晴药业集团股份有限公司 | 杂环化合物在治疗肺疾病中的应用 |
| WO2026158380A1 (zh) * | 2025-01-21 | 2026-07-30 | 正大天晴药业集团股份有限公司 | 含三并环的化合物的药物组合物 |
| WO2025149100A2 (zh) * | 2025-04-29 | 2025-07-17 | 北京泰德制药股份有限公司 | 含有pde4抑制剂化合物a的药物组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI64370C (fi) * | 1977-05-05 | 1983-11-10 | Hoechst Ag | Foerfarande foer framstaellning av terapeutiskt anvaendbara pyimido-(6,1-a)isokinolin-2-imino-4-onderivat |
| ZW6284A1 (en) * | 1983-05-05 | 1985-10-30 | Hoffmann La Roche | Novel pyrimidone derivatives |
| US6473627B1 (en) | 1998-07-22 | 2002-10-29 | Mitsubishi Denki Kabushiki Kaisha | Mobile communication system and mobile communication method |
| DK1165558T3 (da) | 1999-03-31 | 2004-02-09 | Vernalis Ltd | Pyrimido[6,1-a]isoquinolin-4-on-derivater |
| CN101262846A (zh) * | 2005-07-15 | 2008-09-10 | Map药物公司 | 在离散的吸入粒子中结合的多种活性药物成分及其制剂 |
| SI2603509T1 (sl) * | 2010-08-09 | 2014-10-30 | Verona Pharma Plc | Kristalinična oblika spojine PIRIMIDIO(6,1-A) IZOKINOLIN-4-ENA |
| JP6560986B2 (ja) * | 2013-03-15 | 2019-08-14 | ヴェローナ ファーマ ピーエルシー | 複合製剤 |
| LT3193835T (lt) * | 2014-09-15 | 2018-06-11 | Verona Pharma Plc | Skysta inhaliuojama vaisto forma, apimanti rpl554 |
| GB201502260D0 (en) * | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| FI3822272T3 (fi) * | 2018-07-13 | 2025-01-21 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Fuusioitunut trisyklinen yhdiste PDE3:n/PDE4:n kaksoisinhibiittorina |
| PL4092025T3 (pl) * | 2020-01-15 | 2024-10-28 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Kompozycja farmaceutyczna tricyklicznego związku będącego podwójnym inhibitorem pde3/pde4 |
| CN114929701B (zh) * | 2020-01-15 | 2024-11-05 | 正大天晴药业集团股份有限公司 | 一种pde3/pde4双重抑制剂的结晶及其应用 |
-
2021
- 2021-01-15 PL PL21741236.0T patent/PL4092025T3/pl unknown
- 2021-01-15 WO PCT/CN2021/072145 patent/WO2021143841A1/zh not_active Ceased
- 2021-01-15 US US17/792,282 patent/US20230060174A1/en active Pending
- 2021-01-15 JP JP2022543589A patent/JP7712276B2/ja active Active
- 2021-01-15 CA CA3167378A patent/CA3167378A1/en active Pending
- 2021-01-15 CN CN202411808682.9A patent/CN119909076A/zh active Pending
- 2021-01-15 CN CN202180008484.2A patent/CN114929700B/zh active Active
- 2021-01-15 KR KR1020227026829A patent/KR20220127845A/ko active Pending
- 2021-01-15 EP EP21741236.0A patent/EP4092025B9/en active Active
- 2021-01-15 CN CN202411808686.7A patent/CN119792296A/zh active Pending
- 2021-01-15 ES ES21741236T patent/ES2995084T3/es active Active
-
2025
- 2025-07-10 JP JP2025116631A patent/JP2025148464A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025148464A (ja) | 2025-10-07 |
| US20230060174A1 (en) | 2023-03-02 |
| WO2021143841A1 (zh) | 2021-07-22 |
| EP4092025A4 (en) | 2023-08-30 |
| EP4092025B1 (en) | 2024-08-14 |
| AU2021208129A1 (en) | 2022-08-18 |
| CN119792296A (zh) | 2025-04-11 |
| CA3167378A1 (en) | 2021-07-22 |
| CN114929700B (zh) | 2024-11-22 |
| KR20220127845A (ko) | 2022-09-20 |
| JP7712276B2 (ja) | 2025-07-23 |
| EP4092025A1 (en) | 2022-11-23 |
| CN119909076A (zh) | 2025-05-02 |
| EP4092025B9 (en) | 2024-11-06 |
| CN114929700A (zh) | 2022-08-19 |
| ES2995084T3 (en) | 2025-02-05 |
| JP2023512475A (ja) | 2023-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4092025A4 (en) | PHARMACEUTICAL COMPOSITION OF A TRICYCLIC PDE3/PDE4 DOUBLE INHIBITOR COMPOUND | |
| IL280075A (en) | Fused tri-cyclic compound as pde3/pde4 dual inhibitor | |
| IL310442A (en) | FUSED BICYCLIC heteroaryl compounds are useful as NLRP3 inhibitors | |
| AU2024303288A1 (en) | Parp1 inhibitor compounds | |
| EP2244574A4 (en) | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF SYNTHESIS AND AS PDE4 INHIBITORS | |
| EP4076395A4 (en) | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | |
| NZ730134A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| EP4137484A4 (en) | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | |
| IL319360A (en) | Novel compounds as modulators of NLRP3 inhibition | |
| AU2024255473A1 (en) | Pyrazolopyrimidine derivatives as inhibitors of nlrp3 | |
| IL317506A (en) | Tricyclic triazole compounds as fish oil inhibitors | |
| ZA202110347B (en) | Bicyclic compound as rip-1 kinase inhibitor and application thereof | |
| EP4293018A4 (en) | COMPOUND AS NLRP3 INHIBITOR | |
| AU2024356450A1 (en) | Parp1 inhibitor compounds | |
| AU2024354981A1 (en) | Parp1 inhibitor compounds | |
| AU2022211285A9 (en) | Tricyclic compounds as anticancer agents | |
| HK40106117A (en) | Tricyclic compounds as inhibitors of kras | |
| HK40083546A (en) | Tricyclic compounds as inhibitors of kras | |
| IL326691A (en) | Tricyclic heteroaromatic inhibitors of klk5 | |
| CA3273582A1 (en) | Novel compounds as modulators of nlrp3 inhibition | |
| CA3302937A1 (en) | Tricyclic heteroaromatic inhibitors of klk5 | |
| CA3288941A1 (en) | Pyrazolopyrimidine derivatives as inhibitors of nlrp3 | |
| IL321066A (en) | Processes for preparing NLRP3 inhibitor | |
| CA3284710A1 (en) | Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof | |
| HK40109676A (en) | Inhibitors of nlrp3 |